Research Paper Volume 16, Issue 19 pp 12850—12865

Figure 5. MAPK and AKT pathway inhibitors and agonists reverse the impact of USP4 in PTC. (A, B) Western blot analysis for detecting USP4, ERK, AKT, phosphorylated ERK, and phosphorylated AKT in B-CPAP and TPC-1 cells after USP4 knockdown and subsequent treatment with C16-PAF (10 μM for 24 h) or SC79 (4 μg/mL for 24 h); (C–F) CCK-8 assay to evaluate the proliferative capacity of B-CPAP and TPC-1 cells after USP4 knockdown and subsequent treatment with C16-PAF (10 μM for 24 h) or SC79 (4 μg/mL for 24 h); (G, H) Western blot analysis to detect USP4, ERK, AKT, phosphorylated ERK, and phosphorylated AKT in K1 and KTC-1 cells overexpressing USP4 after treatment with U0126 (20 μM for 24 h) or LY294002 (50 μM for 24 h); (I–L) CCK-8 assay to evaluate the proliferative capacity of K1 and KTC-1 cells overexpressing USP4 after treatment with U0126 (20 μM for 24 h) or LY294002 (50 μM for 24 h). All ^*p < 0.05, ^**p < 0.01, ^***p < 0.001, ^****p < 0.0001.